New hope for transplant patients with stubborn CMV infection
NCT ID NCT06577363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection did not improve with standard treatments. Participants take Maribavir tablets as part of their regular care, and doctors monitor side effects and whether the virus clears from the blood for 27 weeks. The goal is to see how well the drug works and what side effects occur in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Better CMV detection for IBD patients: which test works best?
- New study checks if maribavir works safely for transplant patients with stubborn CMV
- New hope for young transplant patients: maribavir trial targets CMV
- New trial aims to stop CMV eye inflammation from returning
- New hope for transplant patients with Drug-Resistant CMV
- Maribavir safety under review for kidney patients with CMV